LianBio Announces Pricing of Initial Public Offering

NEXT STORY
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
PREV STORY
Cortexyme Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Cortexyme, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018

Conference call at 8:30 a.m. EDT, Tuesday, May 15, 2018RUTHERFORD, N.J., May 10, 2018 ...

author_avatar
NASDAQ Market News

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

author_avatar
NASDAQ Market News

Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor

Phase 1/2 clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s immunotherapy INO-5401 in ...

author_avatar
NASDAQ Market News